Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • insm_truth_teller insm_truth_teller Apr 5, 2014 10:49 AM Flag

    Insmed setback as lead therapy flunks&.Insmed is once again hustling to put the best spin possible on a clinical study of its only therapy.

    Insmed setback as lead therapy flunks&.Insmed is once again hustling to put the best spin possible on a clinical study of its only therapy. By John Carroll
    Insmed is once again hustling to put the best spin possible on a clinical study of its only therapy.

    The Monmouth Junction, NJ-based biotech ($INSM) acknowledged that its Phase II study of the inhaled antibiotic Arikayce for nontuberculous mycobacterial (NTM) lung infections failed the primary endpoint--a reduction in bacterial density used as a measure of infection.
    Last summer the biotech's share price was hammered after it posted head-to-head Phase III results for Arikayce against Tobi, a twice-daily antibiotic from Novartis ($NVS) used to prevent lung infections in high-risk CF patients. Tobi actually did a little better than Arikayce but the experimental therapy with the easier dosing schedule was statistically noninferior. Investors blew right past the company's optimism and the stock price was battered

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Insmed setback as lead therapy flunks&.Insmed is once again hustling to put the best spin possible on a clinical study of its only therapy. By John Carroll
      Insmed is once again hustling to put the best spin possible on a clinical study of its only therapy.

      The Monmouth Junction, NJ-based biotech ($INSM) acknowledged that its Phase II study of the inhaled antibiotic Arikayce for nontuberculous mycobacterial (NTM) lung infections failed the primary endpoint--a reduction in bacterial density used as a measure of infection.
      Last summer the biotech's share price was hammered after it posted head-to-head Phase III results for Arikayce against Tobi, a twice-daily antibiotic from Novartis ($NVS) used to prevent lung infections in high-risk CF patients. Tobi actually did a little better than Arikayce but the experimental therapy with the easier dosing schedule was statistically noninferior. Investors blew right past the company's optimism and the stock price was battered

    • Insmed setback as lead therapy flunks&.Insmed is once again hustling to put the best spin possible on a clinical study of its only therapy. By John Carroll
      Insmed is once again hustling to put the best spin possible on a clinical study of its only therapy.

      The Monmouth Junction, NJ-based biotech ($INSM) acknowledged that its Phase II study of the inhaled antibiotic Arikayce for nontuberculous mycobacterial (NTM) lung infections failed the primary endpoint--a reduction in bacterial density used as a measure of infection.
      Last summer the biotech's share price was hammered after it posted head-to-head Phase III results for Arikayce against Tobi, a twice-daily antibiotic from Novartis ($NVS) used to prevent lung infections in high-risk CF patients. Tobi actually did a little better than Arikayce but the experimental therapy with the easier dosing schedule was statistically noninferior. Investors blew right past the company's optimism and the stock price was battered

    • Typical misreporting of facts. We haven't seen any data comparing the mean reduction in mycobacterial density . All we know is that there was not a statistically significant difference in the number of subjects experiencing AT LEAST a one point improvement on the semi-quantitative scale. Looking at the results that way ignores the more clinically important endpoint of ERADICATION of the mycobacteria from the subjects in which Arikayce blew the doors off placebo at the P=0.01 level.

 
INSM
22.12-0.49(-2.17%)May 26 4:00 PMEDT